Ascentage Pharma's olverembatinib, China's first third-generation BCR-ABL1 inhibitor, receives approval in Macau and Chinese mainland for treating resistant CML.
Ascentage Pharma's novel BCR-ABL1 tyrosine kinase inhibitor, olverembatinib, has been approved in Macau China by the Pharmaceutical Administration Bureau for treating adult patients with TKI-resistant chronic-phase chronic myeloid leukemia or accelerated-phase CML harboring the T315I mutation. Olverembatinib, the first third-generation BCR-ABL1 inhibitor approved by China's NMPA, also received initial approvals in the Chinese mainland. The drug is jointly commercialized in China by Ascentage Pharma and Innovent Biologics.
July 08, 2024
3 Articles